Sanuwave Q1 revenue $9.34M (+61% YoY); operating income $1.0M; Q2 guidance 40-50% growth

SANUWAVE Health, Inc.

2025-Q1 EPS reported -$0.66 revenue$9,342,000

Revenue $9.34M, up 61% from $5.79M in Q1 2024; gross margin 79.0% vs 72.6%; GAAP operating income $1.0M.
Adjusted EBITDA $2.3M vs -$59k in Q1 2024; net loss $5.7M driven by change in fair value of derivative liabilities.
UltraMist systems sold: 98 (128% increase from 43); consumables revenue +43% to $5.8M.
Q2 2025 revenue guidance $10.0-10.7M (40-50% YoY); full year 2025 guidance reaffirmed at $48-50M.
CEO highlights strong pipeline, comfortable inventory levels for larger customer engagements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.